OC
PIII icon

Oppenheimer & Co’s P3 Health Partners PIII Stock Holding History

Oppenheimer & Co’s Portfolio PIII Stock Details PIII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-429
Closed -$30.2K – 1495
2023
Q4 		$30.2K Hold
429
– – ﹤0.01% 1364
2023
Q3 		$31.5K Hold
429
– – ﹤0.01% 1356
2023
Q2 		$64.1K Buy
+429
New +$59.3K ﹤0.01% 1371

Other funds holding PIII

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Oppenheimer & Co's PIII Position: Q1 2024 in Review

Oppenheimer & Co sold out of P3 Health Partners (PIII) in Q1 2024, closing a stake of 429 shares — an estimated $30.2K sold.

Oppenheimer & Co first reported a position in PIII in Q2 2023 and held it in 3 quarters. The position peaked at $64.1K in Q2 2023. 62 funds tracked by Wall St. Rank hold PIII as of Q1 2024.

  • Oppenheimer & Co reported no remaining P3 Health Partners position as of Q1 2024 after selling out during the quarter.
  • Oppenheimer & Co sold 429 P3 Health Partners shares in Q1 2024, an estimated $30.2K.
  • Oppenheimer & Co first reported a position in P3 Health Partners in Q2 2023 and held it in 3 quarters.
  • Oppenheimer & Co's P3 Health Partners position peaked at $64.1K in Q2 2023.
  • 62 funds tracked by Wall St. Rank held P3 Health Partners as of Q1 2024.

Based on Oppenheimer & Co's 13F filing for Q1 2024, filed 7 May 2024.